DURHAM, N.C., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be participating in the Stifel 2016 Healthcare Conference and the ROTH Innovations in Oncology Corporate Access Day. The Stifel 2016 Healthcare Conference will take place November 15-16 at the Lotte New York Palace in New York City. Argos management will be presenting on Wednesday, November 16 th from 2:15-2:55pm ET in the Holmes II room, as well as conducting pre-arranged 1x1 meetings. See http://www.stifel.com/institutional/ConferenceAndEvents for further details. The ROTH Innovations in Oncology Corporate Access Day will also be held at the Lotte New York Palace on Thursday, November 17 th. The event will consist of pre-arranged 1x1 meetings with no formal presentation. See http://www.roth.com/main/Page.aspx?PageID=7005 for further details. About the Arcelis® Technology PlatformArcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient's individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient's own dendritic cells, which are optimized from cells collected by a leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient's plasma, and administered via intradermal injection as an individualized immunotherapy.